The deal will see Mammoth partner with Vertex Pharmaceuticals to develop gene-editing therapies to be delivered directly into the body.
Mammoth Biosciences Inks $691 Million Deal To Develop Crispr Gene-Editing Therapies
The deal will see Mammoth partner with Vertex Pharmaceuticals to develop gene-editing therapies to be delivered directly into the body.